Pediatric Ototoxicity: Current Trends and Management

Fligor, Brian J.

doi:10.1055/s-0039-1684044

Cited by 23 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study has reported that 80% of CDDP-treated patients (388 of 488) experience hearing loss of at least 20 dB, and 40% experience tinnitus [1]. The incidence of CDDP-induced ototoxicity in children ranges from 22 to 77% [2], among which 63%-77% of children experience permanent sensorineural hearing loss [3,4]. Children are at greater risk of CDDP-induced ototoxicity than adults, thus resulting in severe negative consequences in their neurocognitive ability and psychosocial development [5].…”

Section: Introductionmentioning

confidence: 99%

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Chen

Tong

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

Background: Ototoxicity is one of the major side effects of platinum-based chemotherapy, especially cisplatin therapy. To date, no FDA approved agents to alleviate or prevent this ototoxicity are available. However, ototoxicity is generally believed to be produced by excessive generation of reactive oxygen species (ROS) in the inner ear, thus leading to the development of various antioxidants, which act as otoprotective agents. Astaxanthin (ATX) is an interesting candidate in the development of new therapies for preventing and treating oxidative stress-related pathologies, owing to its unique antioxidant capacity. Methods and results:In this study, we aimed to evaluate the potential antioxidant properties of ATX in the inner ear by using the HEI-OC1 cell line, zebrafish, and guinea pigs. Because ATX has poor solubility and cannot pass through round window membranes (RWM), we established lipid-polymer hybrid nanoparticles (LPN) for loading ATX. The LPN enabled ATX to penetrate RWM and maintain concentrations in the perilymph in the inner ear for 24 h after a single injection. ATX-LPN were found to have favorable biocompatibility and to strongly affect cisplatin-induced generation of ROS, on the basis of DCFHDA staining in HEI-OC1 cells. JC-1 and MitoTracker Green staining suggested that ATX-LPN successfully reversed the decrease in mitochondrial membrane potential induced by cisplatin in vitro and rescued cells from early stages of apoptosis, as demonstrated by FACS stained with Annexin V-FITC/PI. Moreover, ATX-LPN successfully attenuated OHC losses in cultured organ of Corti and animal models (zebrafish and guinea pigs) in vivo. In investigating the protective mechanism of ATX-LPN, we found that ATX-LPN decreased the expression of pro-apoptotic proteins (caspase 3/9 and cytochrome-c) and increased expression of the anti-apoptotic protein Bcl-2. In addition, the activation of JNK induced by CDDP was up-regulated and then decreased after the administration of ATX-LPN, while P38 stayed unchanged. Conclusions:To best of our knowledge, this is first study concluded that ATX-LPN as a new therapeutic agent for the prevention of cisplatin-induced ototoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Chen

Tong

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…En la figura 2 se resumen los posibles resultados que pueden hallarse en los niños tratados con cisplatino. Los grados 0 a se pueden asignar en función de la gravedad de la hipoacusia y ninguno requiere evaluar más de tres frecuencias (Fligor, 2019).…”

Section: Estrategias De Monitorización Audiológica Y Seguimientounclassified

Prevención y diagnóstico precoz de la sordera por ototóxicos Recomendaciones CODEPEH 2020

Batalla¹,

Casaubón

Canet

et al. 2021

Redis

View full text Add to dashboard Cite

show abstract

“…According to clinical protocols and the recommendations of scientific societies, monitoring for early detection of ototoxicity allows treatment regimens to be changed and hence can minimize, or even prevent, ototoxicity leading to balance impairments and/or hearing loss (40,44,45). According to the American Academy of Audiology (AAA), sensorineural degradation and auditory damage can lead to permanent hearing loss and tinnitus.…”

Section: Ototoxicity As An Adverse Effect Of Drugsmentioning

confidence: 99%

Ototoxicity of Drugs Used in the Treatment of Covid-19

Skarżyńska¹,

Król²,

Czajka³

et al. 2020

J Hear Sci

View full text Add to dashboard Cite

Background: Actual level of knowledge of treatment of COVID-19 disease caused by a type of coronavirus is that the disease cannot at present be cured by targeted therapy. Worldwide research is aiming to find a specific treatment, such as a vaccine or drug, for this type of coronavirus; this may help improve the situation, but it is highly expensive and time-consuming. The purpose of this paper is to review drug therapies approved in different parts of the world to treat COVID-19 and draw attention to ototoxicity as one of the adverse side-effects.Material and methods: Review of current literature was done in the scientific databases PubMed, ResearchGate, GoogleScholar, and Science-Direct. Studies were reviewed with reference to the inclusion criteria, then graded to assess the internal and external validity, leaving 50 studies for review.Results: According to scientific reports, possible antiviral pharmacological agents to treat COVID-19 consist of chloroquine, hydroxychloroquine, azitromycine, oseltamivir, and tocilizumab. In some cases, certain combinations may lead to additive ototoxicity as an adverse effect. Ototoxicity may be manifested by sensory and nervous hearing loss, tinnitus, imbalance, and cochlear-mandibular symptoms, which are sometimes temporary but sometimes permanent. Conclusion:Drug ototoxicity is well known as a cause of cochlear hearing loss, and so the use of new pharmacotherapy methods and drug combinations in the fight against the new coronavirus may have harmful effects. Ototoxicity needs to be taken into account.

show abstract

Pediatric Ototoxicity: Current Trends and Management

Cited by 23 publications

References 27 publications

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Prevención y diagnóstico precoz de la sordera por ototóxicos Recomendaciones CODEPEH 2020

Ototoxicity of Drugs Used in the Treatment of Covid-19

Contact Info

Product

Resources

About